Stockscreener 앱 받기
9.47
12.07%
1.02
시장 영업 전:
9.48
0.010
+0.11%
전일 마감가:
$8.45
열려 있는:
$8.68
하루 거래량:
672.98K
Relative Volume:
0.54
시가총액:
$511.75M
수익:
$2.80M
순이익/손실:
$-122.23M
주가수익비율:
-4.1462
EPS:
-2.284
순현금흐름:
$-46.53M
1주 성능:
+9.29%
1개월 성능:
+22.35%
6개월 성능:
-41.94%
1년 성능:
+24.12%
1일 변동 폭
$8.67
$9.57
1주일 범위
$8.12
$9.57
52주 변동 폭
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
명칭
Upstream Bio Inc
전화
781-208-2466
주소
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
9.47 | 511.75M | 2.80M | -122.23M | -46.53M | -2.284 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Evercore ISI | Outperform |
| 2025-10-14 | 개시 | Truist | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
모두보기
Upstream Bio Inc 주식(UPB)의 최신 뉴스
Upstream Bio (NASDAQ:UPB) Trading Up 11.2%What's Next? - MarketBeat
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Aug EndMonth: What is the next catalyst for Upstream Bio IncMarket Trend Report & Stock Timing and Entry Methods - baoquankhu1.vn
Upstream Bio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
UPB | Upstream Bio, Inc. Common Insider Trading - Quiver Quantitative
Upstream Bio CFO Gray sells $7915 in shares - Investing.com
Upstream Bio CFO Gray sells $7915 in shares By Investing.com - Investing.com South Africa
Upstream Bio CEO Makes Notable Move With Fresh Stock Sale - TipRanks
Upstream Bio (UPB) CFO executes automatic share sale to cover RSU taxes - Stock Titan
Upstream Bio (UPB) CMO auto-sells 894 shares to cover RSU taxes - Stock Titan
Tax-related sale: Upstream Bio (UPB) CEO automatically sells 2,093 shares - Stock Titan
Tax-withholding share sale by Upstream Bio (UPB) General Counsel disclosed - Stock Titan
Tax-related stock sale by Upstream Bio (UPB) chief business officer - Stock Titan
Risk Recap: Whats next for Upstream Bio Inc stockM&A Rumor & Short-Term Swing Trade Alerts - baoquankhu1.vn
Integral Health Asset Management LLC Acquires New Stake in Upstream Bio, Inc. $UPB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 14.4% HigherShould You Buy? - MarketBeat
UPB: Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing - TradingView
UPB: Verekitug's quarterly dosing shows robust efficacy, with phase 3 and COPD programs advancing - TradingView
Upstream Bio, Inc. CEO joins Leerink Partners fireside chat at global healthcare conference - Traders Union
Dip Buying: Is Upstream Bio Inc forming a breakout pattern2025 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Upstream Bio's selloff may be 'overdone,' but analyst highlights asthma drug's competitive edge concerns - MSN
Aug Sectors: Can Upstream Bio Inc deliver consistent dividendsJuly 2025 Outlook & Community Verified Watchlist Alerts - baoquankhu1.vn
Lifesci Capital Forecasts Upstream Bio Q2 Earnings - MarketBeat
Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $45.25 - Defense World
Why Did UPB Stock Plunge 40% Today? - Stocktwits
RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio presents additional Phase 2 data for verekitug - Investing.com South Africa
Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com Canada
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView
Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com - Investing.com Australia
Upstream Bio to present verekitug CRSwNP trial data at AAAAI - Investing.com
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Bitget
UPB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Latest UPB NewsUpstream Bio Reports Fourth Quarter and Full... - Stock Titan
Upstream Bio to Participate in Investor Conferences in March 2026 - geneonline.com
Peering Into Upstream Bio Inc's Recent Short Interest - Benzinga
Upstream Bio announces participation in major healthcare conferences - Traders Union
Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewswire
Insider Trends: Is Upstream Bio Inc a defensive stockTrade Entry Summary & Community Driven Trade Alerts - baoquankhu1.vn
Can Upstream Bio Inc. ride the EV waveJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru
Upstream Bio Inc (UPB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Upstream Bio Inc 주식 (UPB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
1.82%
자본화:
|
볼륨(24시간):